Cagrilintide is a long-acting amylin analog developed by Novo Nordisk and studied in the context of body-weight and metabolic research. Unlike the GLP-1 receptor agonists that dominate current headlines, cagrilintide works through a different but complementary hormonal pathway — the amylin system — and has been investigated both on its own and in fixed-dose combination with semaglutide, under the name CagriSema. This article summarizes what is currently known about cagrilintide’s mechanism, the published trial record, and general handling considerations relevant to laboratory research.
What is Cagrilintide?
Cagrilintide is a synthetic, long-acting analog of amylin, a peptide hormone that is co-secreted with insulin from pancreatic beta cells in response to meals. Natural amylin has a very short half-life and plays a role in regulating satiety, gastric emptying, and glucagon secretion, but it is not practical for once-weekly dosing in its native form.
To extend its duration of action, cagrilintide was engineered with structural modifications — including fatty-acid acylation for albumin binding — conceptually similar to the approach used for long-acting GLP-1 analogs such as semaglutide. This engineering supports once-weekly subcutaneous administration in research protocols, in contrast to the much more frequent dosing that would otherwise be required with native amylin.
Cagrilintide is being developed by Novo Nordisk, the same company responsible for semaglutide, and much of the cagrilintide research program has been designed from the outset around eventual pairing with semaglutide. For dosing-reference material, see the Cagrilintide 5mg guide and the Cagrilintide 10mg guide.
Mechanism of Action
Cagrilintide is described in the pharmacology literature as a dual amylin and calcitonin receptor agonist (DACRA) — it engages both the amylin receptor and, to a meaningful degree, the calcitonin receptor. Recent structural work using cryo-EM has characterized how cagrilintide binds these receptor complexes and why its binding mode differs subtly from native amylin, potentially contributing to its extended activity profile (Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors, Nature Communications, 2025).
At a physiological level, three effects are consistently described:
1. Central Satiety Signaling
Amylin receptors are expressed in areas of the hindbrain and hypothalamus involved in appetite regulation. Activation of these pathways is associated with increased feelings of fullness and a reduction in the drive to eat, operating in parallel with — rather than duplicating — GLP-1’s central appetite effects.
2. Slowed Gastric Emptying
Cagrilintide slows the rate at which stomach contents move into the small intestine. This prolongs the sensation of fullness after a meal and, in preclinical models, has been linked to reduced overall food intake.
3. Complementary, Non-Overlapping Pathway to GLP-1
Because amylin and GLP-1 signal through distinct receptor systems, cagrilintide’s effects are considered mechanistically complementary rather than redundant when paired with a GLP-1 agonist. This is the pharmacological rationale for studying cagrilintide together with semaglutide as CagriSema — see the CagriSema 10mg guide for co-formulation reference material, and the GLP-1 comparison overview for how amylin-based approaches fit alongside single- and multi-agonist incretin peptides.
Research Background and Key Findings
Phase 2 Dose-Finding — Monotherapy
The foundational cagrilintide monotherapy dataset comes from Lau et al. (2021), a multicentre, randomised, double-blind, placebo- and active-controlled, dose-finding phase 2 trial published in The Lancet. Participants with overweight or obesity (without diabetes) were randomized across a range of once-weekly cagrilintide doses (0.3, 0.6, 1.2, 2.4, and 4.5 mg). The trial reported dose-dependent reductions in body weight over 26 weeks, with the highest studied dose (4.5 mg) associated with substantially greater mean weight loss than placebo. This trial established the tolerability profile and dose-response relationship that shaped subsequent combination research.
Phase 1b Concomitant Administration with Semaglutide
Enebo et al. (2021), also published in The Lancet, reported a randomised, controlled phase 1b trial examining the safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide co-administered with semaglutide 2.4 mg. This study was designed specifically to characterize whether the two peptides could be safely combined and whether their pharmacokinetic profiles were compatible with once-weekly co-dosing — a necessary step before larger combination trials could proceed.
Phase 2 Combination Trial in Type 2 Diabetes
A subsequent phase 2 trial (reported in The Lancet, 2023) evaluated co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in participants with type 2 diabetes, comparing the combination against semaglutide alone in an active-controlled design. This trial provided early efficacy signals supporting further development of the fixed-dose combination.
Later-Stage CagriSema Development
Building on these earlier studies, Novo Nordisk’s REDEFINE and REIMAGINE phase 3 programs have since evaluated the fixed-dose CagriSema combination in larger populations with obesity and with type 2 diabetes, with results reported at major diabetes conferences and in peer-reviewed journals through 2025 and 2026. These later trials are separate from — but built directly upon — the cagrilintide monotherapy and concomitant-dosing work summarized above, and readers interested in the broader competitive landscape may find the next-gen weight loss peptides overview useful context.
- 1
Phase 2 monotherapy (Lau, 2021)
Dose-finding 0.3-4.5 mg over 26 weeks; established dose-response and tolerability.
- 2
Phase 1b combination (Enebo, 2021)
Cagrilintide co-administered with semaglutide 2.4 mg; confirmed compatible PK for co-dosing.
- 3
Phase 2 in type 2 diabetes (2023)
Cagrilintide 2.4 mg + semaglutide 2.4 mg vs semaglutide alone; early efficacy signals.
- 4
Phase 3 REDEFINE / REIMAGINE (2025-2026)
Fixed-dose CagriSema evaluated in larger obesity and T2D populations.
It is important to note that trial designs, endpoints, and populations differ across these studies, so results are not directly interchangeable, and ongoing phase 3 and regulatory review work means the evidence base continues to evolve.
Forms, Reconstitution & Handling
In research settings, cagrilintide is typically supplied as a lyophilized (freeze-dried) powder in a sealed vial, which must be reconstituted with bacteriostatic water before use in a laboratory context. General handling points described in the literature and common laboratory practice include:
- Bringing the vial to room temperature before reconstitution
- Adding diluent slowly down the interior wall of the vial rather than directly onto the powder
- Swirling gently rather than shaking, to avoid denaturing the peptide
- Confirming the solution is clear and free of visible particulate before proceeding
- Recording the reconstitution date on the vial label for tracking stability
Cagrilintide is also studied as part of a fixed-ratio co-formulation with semaglutide (CagriSema), where the labeled mass refers to combined peptide content rather than either component individually — see the CagriSema 10mg guide for a worked example of how combined-dose vials are typically labeled and calculated.
This section is a general overview, not step-by-step instructions; researchers should consult institutional protocols and the peptide reconstitution guide for technique-level detail.
Research Considerations
Published cagrilintide research has generally used a gradual dose-escalation design, incrementally increasing the weekly amount over a period of weeks. This general pattern — a design choice motivated by the aim of allowing physiological adaptation and reducing transient gastrointestinal effects — mirrors the approach used for GLP-1 agonists such as semaglutide, and is described in the primary literature purely as part of trial methodology, not as instruction. Any discussion of specific amounts in the sections above and in linked reference material reflects what has been reported in the published dose-finding literature; it is not medical guidance and should not be interpreted as a protocol to follow.
Researchers examining amylin-pathway peptides alongside other incretin-based candidates may also find it useful to review how cagrilintide’s single-pathway profile differs from multi-agonist molecules discussed in the GLP-1 comparison article.
Storage & Stability
General storage principles reported for lyophilized amylin-analog peptides, consistent with manufacturer and laboratory guidance for similar molecules:
- Lyophilized powder: store frozen, typically around -20°C, protected from light and moisture
- Reconstituted solution: refrigerate at approximately 2-8°C
- In-use stability: commonly cited as roughly 4-6 weeks once reconstituted and refrigerated
- Avoid repeated freeze-thaw cycles, which can degrade peptide integrity
- Discard any solution that appears cloudy, discolored, or contains visible particulate
Safety, Legality & Research Disclaimers
Cagrilintide, whether studied alone or as part of the CagriSema combination, is a research chemical in the contexts discussed here — it is not an approved pharmaceutical product for general human use in most jurisdictions, and this article does not describe or endorse human administration. Material sold for research purposes is not manufactured to pharmaceutical-grade standards for human consumption and should be handled only within appropriate laboratory, institutional, and regulatory frameworks.
Legal status varies by country and evolves as regulatory reviews of CagriSema and related compounds progress; researchers are responsible for verifying current rules in their own jurisdiction and institution before acquiring or handling any research peptide. Nothing in this article constitutes medical advice, and none of the amounts or schedules discussed should be treated as instructions for self-administration.
Frequently Asked Questions
What is cagrilintide, in simple terms?
It is a long-acting, synthetic analog of amylin, a natural pancreatic hormone, engineered for once-weekly research administration and studied for its effects on satiety and body weight.
How is cagrilintide different from semaglutide?
Semaglutide acts on the GLP-1 receptor, while cagrilintide acts on amylin and calcitonin receptors. The two pathways are considered complementary, which is why they have been studied together as CagriSema rather than as substitutes for one another.
What is CagriSema?
CagriSema is a fixed-dose co-formulation of cagrilintide and semaglutide, studied in phase 2 and phase 3 trials for its combined effect on body weight and glycemic parameters. See the CagriSema 10mg guide for reference material.
Is cagrilintide the same thing as amylin?
No. It is a modified analog designed to resist rapid degradation and support once-weekly dosing, unlike native amylin, which has a very short half-life.
What did the key phase 2 trial find?
Lau et al. (2021) reported dose-dependent body-weight reductions across a range of once-weekly cagrilintide doses over 26 weeks in a placebo- and active-controlled trial, with the highest dose studied showing the largest effect.
Is research-grade cagrilintide approved for human use?
No. It is supplied strictly for laboratory research purposes and is not an approved medicine; regulatory review of CagriSema-based products is ongoing in various jurisdictions.
Conclusion
Cagrilintide illustrates how amylin-pathway biology offers a genuinely distinct — and potentially complementary — angle on body-weight and metabolic research compared with GLP-1-centered approaches. Its once-weekly pharmacokinetics, the foundational phase 2 dose-finding data from Lau et al. (2021), and the concomitant-dosing groundwork from Enebo et al. (2021) collectively explain why cagrilintide became a natural candidate for combination with semaglutide. As the CagriSema clinical program continues to mature, cagrilintide is likely to remain a reference point for amylin-based research in the broader metabolic peptide literature.
References
- Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” The Lancet. 2021;398(10317):2160-2172.
- Enebo LB, Berthelsen KK, Kankam M, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.” The Lancet. 2021.
- Frias JP, et al. “Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in participants with type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” The Lancet. 2023.
- “Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.” Nature Communications. 2025.
- Garvey WT, et al. CagriSema phase 3 REDEFINE 1 trial results in adults with overweight or obesity. New England Journal of Medicine. 2025.
Last updated: July 4, 2026
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption.